Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Vaccine

• Publication date

  2011-01-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.vaccine.2010.06.003PMID 20600491
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Plasma exchange for Guillain-Barré syndrome.

  2017cited by this paper
• Chapter 3 – INFANCY AND TODDLER YEARS

  2009cited by this paper
• Anti-ganglioside antibody induction by swine (A/NJ/1976/H1N1) and other influenza vaccines: insights into vaccine-associated Guillain-Barré syndrome.

  2008cited by this paper
• The Epidemiology of Guillain-Barré Syndrome Worldwide

  2008cited by this paper
• The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.

  2008cited by this paper
• A local reaction at or near injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety data.

  2008cited by this paper
• [Infectious agents as the triggers for the pathogenesis of the neuroimmunological disorders].

  2008cited by this paper
• Neurophysiological criteria in the diagnosis of different clinical types of Guillain–Barre syndrome

  2007cited by this paper
• The development of standardized case definitions and guidelines for adverse events following immunization.

  2007cited by this paper
• The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies

  2007cited by this paper
• The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies

  2007cited by this paper
• Immunotherapy for Guillain-Barré syndrome: a systematic review.

  2007cited by this paper
• The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.

  2007cited by this paper
• Swelling at or near injection site: case definition and guidelines for collection, analysis and presentation of immunization safety data.

  2007cited by this paper
• Improved Serological Diagnosis Stresses the Major Role of Campylobacter jejuni in Triggering Guillain-Barré Syndrome

  2006cited by this paper
• No association between immunization and Guillain-Barré syndrome in the United Kingdom, 1992 to 2000.

  2006cited by this paper
• Neurologic complications after surgery for obesity

  2006cited by this paper
• Guillain-Barré syndrome after influenza vaccination in adults: a population-based study.

  2006cited by this paper
• Chapter 34 Guillain-Barré syndrome

  2006cited by this paper
• Acute motor and sensory axonal neuropathy in Burkitt‐like lymphoma

  2006cited by this paper
• Influenza, Campylobacter and Mycoplasma Infections, and Hospital Admissions for Guillain-Barré Syndrome, England

  2006cited by this paper
• The immunobiology of Guillain‐Barré syndromes

  2005cited by this paper
• SeminarGuillain-Barré syndrome

  2005cited by this paper
• Distinguishing acute-onset CIDP from Guillain–Barré syndrome with treatment related fluctuations

  2005cited by this paper
• Recent developments in Miller Fisher syndrome and related disorders

  2005cited by this paper
• Respiratory dysfunction in guillain-barré syndrome

  2004cited by this paper
• Guillain-Barré syndrome

  2004cited by this paper
• Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: the TREND statement.

  2004cited by this paper
• Intravenous immunoglobulin for Guillain-Barré syndrome.

  2004cited by this paper
• Electrodiagnostic criteria for acute and chronic inflammatory demyelinating polyradiculoneuropathy

  2004cited by this paper
• Acute motor axonal neuropathy after Mycoplasma infection

  2004cited by this paper
• Guillain-Barré syndrome in children.

  2004cited by this paper
• Guillain-Barré syndrome following influenza vaccination

  2004cited by this paper
• Practice parameter: Immunotherapy for Guillain-Barré syndrome: Report of the Quality Standards Subcommittee of the American Academy of Neurology

  2004cited by this paper
• Molecular mimicry: Cross‐reactive antibodies from patients with immune‐mediated neurologic disease inhibit neuronal firing

  2004cited by this paper
• Interpretation of traumatic lumbar punctures: who can go home?

  2003cited by this paper
• Handbook of clinical neurophysiology

  2003cited by this paper
• Functional Activation of Myelin-Specific T Cells by Virus-Induced Molecular Mimicry1

  2002cited by this paper
• The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials

  2001cited by this paper
• Multiple pathways to induction of virus-induced autoimmune demyelination: lessons from Theiler's virus infection.

  2001cited by this paper
• Epidemiology of the Guillain-Barré syndrome

  2001cited by this paper
• The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials.

  2001cited by this paper
• The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials.

  2001cited by this paper
• Miller Fisher syndrome: axonal, demyelinating or both?

  2000cited by this paper
• Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group.

  2000cited by this paper
• Long-term outcome in patients with Guillain–Barré syndrome requiring mechanical ventilation

  2000cited by this paper
• Miller Fisher Syndrome: A Hospital-Based Retrospective Study

  2000cited by this paper
• New Concepts of Guillain-Barré Syndrome

  2000cited by this paper
• Corticosteroids for treating Guillain-Barré syndrome.

  2000cited by this paper
• Corticosteroids for treating Guillain-Barré syndrome.

  2000cited by this paper
• Guillain-Barré syndrome: perspectives with infants and children.

  2000cited by this paper
• Pathogenesis of Guillain-Barré syndrome.

  1999cited by this paper
• Improving the Quality of Reports of Meta-Analyses of Randomised Controlled Trials: The QUOROM Statement

  1999cited by this paper
• Association of HLA and T‐cell receptor gene polymorphisms with Semple rabies vaccine–induced autoimmune encephalomyelitis

  1999cited by this paper
• Haemophilus influenzae has a GM1 ganglioside-like structure and elicits Guillain–Barré syndrome

  1999cited by this paper
• Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses.

  1999cited by this paper
• The frequency of clinical variants of Guillain-Barré syndrome in Ferrara, Italy

  1999cited by this paper
• The spectrum of antecedent infections in Guillain-Barré syndrome

  1998cited by this paper
• Anti-GQl b IgG antibody activities related to the severity of Miller Fisher syndrome

  1998cited by this paper
• Epidemiological study of Guillain-Barré syndrome in south east England

  1998cited by this paper
• Anti-GQ1b IgG antibody activities related to the severity of Miller Fisher syndrome.

  1998cited by this paper
• Electrophysiological classification of guillain‐barré syndrome: Clinical associations and outcome

  1998cited by this paper
• The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines.

  1998cited by this paper
• Neuronal molecular mimicry in immune‐mediated neurologic disease

  1998cited by this paper
• Clinical and epidemiologic features of Guillain-Barré syndrome.

  1997cited by this paper
• Do corticosteroids influence the disease course or mortality in Guillain-Barre' syndrome?

  1996cited by this paper
• Pathology of the motor‐sensory axonal Guillain‐Barré syndrome

  1996cited by this paper
• Guillain‐Barré syndrome in children

  1995cited by this paper
• Electrodiagnostic criteria for polyneuropathy and demyelination: application in 135 patients with Guillain-Barré syndrome. Dutch Guillain-Barré Study Group.

  1995cited by this paper
• Guillain-Barré syndrome in northern China. The spectrum of neuropathological changes in clinically defined cases.

  1995cited by this paper
• Campylobacter jejuni infection and Guillain-Barré syndrome.

  1995cited by this paper
• Prognostic factors in Guillain-Barre' syndrome.

  1994cited by this paper
• Acute motor axonal neuropathy: A frequent cause of acute flaccid paralysis in China

  1993cited by this paper
• Plasma exchange treatment and prognosis of Guillain-Barré syndrome.

  1992cited by this paper
• High-Dose Intravenous Immune Globulin in the Management of Severe Guillain-Barre Syndrome

  1992cited by this paper
• Current diagnostic criteria for guillain‐barré syndrome

  1991cited by this paper
• Guillain-Barré syndrome and influenza vaccination in the US Army, 1980-1988.

  1991cited by this paper
• Reassessment of the association between Guillain-Barré syndrome and receipt of swine influenza vaccine in 1976-1977: results of a two-state study. Expert Neurology Group.

  1991cited by this paper
• Electrophysiology in Gullian‐Barré syndeome

  1990cited by this paper
• Electrophysiology in Guillain-Barré syndrome.

  1990cited by this paper
• Assessment of current diagnostic criteria for Guillain‐Barré syndrome

  1990cited by this paper
• Guillain‐Barré syndrome: Historical aspects

  1990cited by this paper
• The epidemiology of Guillain‐Barré syndrome

  1990cited by this paper
• Immunologic studies of rabies vaccination‐induced Guillain‐Barré syndrome

  1988cited by this paper
• Neurologic complications of Semple‐type rabies vaccine

  1987cited by this paper
• Neuropathy in the Miller Fisher syndrome

  1987cited by this paper
• Myelin basic protein as an encephalitogen in encephalomyelitis and polyneuritis following rabies vaccination.

  1987cited by this paper
• Guillain‐Barré syndrome in the United States, 1978–1981

  1983cited by this paper
• Guillain-Barré Syndrome: The Swine Influenza Virus Vaccine Incident in the United States of America, 1976–77: Preliminary Communication

  1979cited by this paper
• Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976--1977.

  1979cited by this paper
• Epidemiology of Guillain-Barré syndrome.

  1978cited by this paper
• Diagnostic criteria for the Guillain-Barré syndrome. An analysis of 50 cases.

  1971cited by this paper
• Nelson Textbook of Pediatrics

  1965cited by this paper
• American Journal of Epidemiology Original Contribution Investigation of the Temporal Association of Guillain-barré Syndrome with Influenza Vaccine and Influenzalike Illness Using the United Kingdom General Practice Research Database

  year unknowncited by this paper

• Accuracy of ICD and SNOMED search strategies for adverse events following COVID-19 vaccination: Analysis of hospital administrative data.

  2026cites this paper
• Immunotherapies on Guillain-Barré syndrome and other acute autoimmune neuropathies.

  2026cites this paper
• Post-licensure safety surveillance of 9-valent human papillomavirus vaccine using the vaccine adverse event reporting system, 2014–2024

  2026cites this paper
• Frequency of Urinary Retention in Guillain-Barré Syndrome Patients

  2026cites this paper
• Analysis of the incidence status and risk factors for immune-mediated neuropathies: a single-center case-control study.

  2026cites this paper
• Guillain-Barré syndrome after the Zika epidemic in Colombia: A multicenter, matched case-control study

  2025cites this paper
• Vaccines and the risk of Guillain-Barré syndrome: A French pharmacovigilance analysis.

  2025cites this paper
• Albuminocytologic Dissociation and the Impact of Age-Adjusted Cerebrospinal Fluid Protein Levels in Guillain–Barré Syndrome

  2025influential citation
• Dengue virus infection and Guillain–Barré syndrome: a systematic review of clinical characteristics, outcomes, and predictors of severity

  2025cites this paper
• Guillain–Barré Syndrome During the Outbreak of Omicron in Southern China: A Multicenter Case-Control Study

  2025cites this paper
• Clinical analysis of the development of Guillain-Barré syndrome during bortezomib treatment for multiple myeloma

  2025cites this paper
• Post-marketing safety surveillance for the recombinant zoster vaccine (Shingrix), vaccine adverse event reporting system, United States, October 2017–April 2024

  2025cites this paper
• Prognostic factors of mechanical ventilation in Guillain–Barré syndrome among adults and children in Vietnam

  2025cites this paper
• A Post-Authorisation Safety Study of a Respiratory Syncytial Virus Vaccine in Pregnant Women and Their Offspring in a Real-World Setting: Generic Protocol for a Target Trial Emulation

  2025cites this paper
• Establishing a Multicenter Active Adverse Events Following Immunization Sentinel Surveillance Network Across 22 Tertiary Care Hospitals in India: Protocol for a Prospective Observational Study

  2025cites this paper
• Safety monitoring of Pfizer's Respiratory Syncytial Virus Vaccine in pregnant women in the Vaccine Adverse Event Reporting System (VAERS), 2023-2024, United States.

  2025cites this paper
• Viral agents in neuromuscular pathology.

  2025cites this paper
• Effectiveness and Safety of Respiratory Syncytial Virus Vaccine for US Adults Aged 60 Years or Older

  2025cites this paper
• Role of neutrophil-to-lymphocyte ratio as a prognostic marker for Guillain-Barre syndrome: a Cross-sectional study from a tertiary care Hospital

  2025cites this paper
• Guillain–Barré syndrome and albuminocytological dissociation: a narrative review

  2025cites this paper
• Association of interleukins 17A and 22 levels and their common genetic polymorphisms in Guillain Barré syndrome.

  2025cites this paper
• Hyperacute Guillain-Barré Syndrome Reaching Clinical Nadir Within 16 Hours: A Case Report.

  2025cites this paper
• The safety of co-administration of recombinant zoster vaccine (Shingrix) and influenza vaccines in the elderly in VAERS during 2018–2024

  2025cites this paper
• Beta-trace protein in chronic inflammatory demyelinating polyradiculoneuropathy and Guillain-Barré syndrome - clinical utilization and a new insight into pathophysiological mechanisms.

  2025cites this paper
• Incidence of Guillain–Barré syndrome in Cuba before and during the Oropouche virus emergency, 2018–2024

  2025cites this paper
• Onset of Guillain Barré Syndrome in a Pregnant Woman: A Report of a Rare Occurrence

  2025cites this paper
• Sequential administration of efgartigimod shortened the course of Guillain–Barré syndrome: a case series

  2025cites this paper
• Correlation between Electrodiagnostic Findings and Cerebrospinal Fluid Changes in Children with Guillain-Barre syndrome

  2025cites this paper
• Temporal Association Between Dengue Outbreaks and Neurologic Autoimmune Diseases in French Guiana

  2025cites this paper
• Autoimmune neuropathies: New guidelines and expert insights into clinical decision making.

  2025cites this paper
• Brain‐Derived Tau as an Outcome Marker in Guillain‐Barré Syndrome: A Retrospective Cohort Study

  2025cites this paper
• MuSK-myasthenia gravis in a patient with overlap syndrome — Bickerstaff encephalitis and pharyngo-cervico-brachial variant of Guillain-Barré syndrome

  2025cites this paper
• Assessing the risk of Guillain-Barré syndrome in older adults after bivalent RSV pre-F vaccination in England

  2025cites this paper
• Rethinking the Brighton Criteria for pediatric Guillain-Barré syndrome: Toward clinical flexibility and global relevance.

  2025cites this paper
• Rhombencephalitis associated with varicella-zoster virus masquerading as Guillain-Barré syndrome

  2025influential citation
• Risk of Guillain-Barré syndrome after COVID-19 vaccination or SARS-CoV-2 infection: A multinational self-controlled case series study.

  2025cites this paper
• Incidence and characteristics of Guillain–Barré syndrome in Taiwan before and during the COVID-19 pandemic: A 12-year single-center experience

  2025cites this paper
• Blood bile acid profiles in chronic inflammatory demyelinating polyneuropathy.

  2025cites this paper
• Adverse Events and Immunization Errors Following a Mass Immunization Campaignwith TAK‐003 in Dourados, Brazil: A Post‐Marketing Safety Surveillance Analysis

  2025cites this paper
• A case report of zoster-induced Guillain–Barré syndrome: diagnostic challenges and potential role of pulse prednisone

  2025influential citation
• Enhanced adenoviral reactivity in Guillain-Barré syndrome after SARS-CoV-2 infection and vaccination.

  2025cites this paper
• Nerve ultrasound as an adjunct to nerve conduction studies in Guillain–Barré syndrome diagnosis: a prospective Egyptian case–control study

  2025cites this paper
• Frequency of Guillain‐Barré Syndrome During the COVID‐19 Pandemic: A Multicenter Study

  2025influential citation
• Guillain-Barré Syndrome and Variants.

  2025cites this paper
• The changing landscape of primary autoimmune neuropathies

  2025cites this paper
• Characterization of Autonomic Involvement in Various Subtypes of Guillain‐Barré Syndrome and Association With Electrophysiological Parameters

  2025cites this paper
• Plasma periaxin is a biomarker of peripheral nerve demyelination.

  2025cites this paper
• Neurological adverse events following COVID-19 vaccination among Canadians referred to the special immunization clinic network.

  2025cites this paper
• Treatment-Related Fluctuation in Guillain-Barre Syndrome With the Acute Motor-Sensory Axonal Neuropathy (AMSAN) Variant: A Case Report

  2024cites this paper
• Electrodiagnostic subtyping in Guillain–Barré syndrome patients in the International Guillain–Barré Outcome Study

  2024cites this paper
• Pattern, causes and functional outcome of peripheral neuropathies in the Amazon region

  2024cites this paper
• A unique case report on campylobacter rectus infection leading to acute motor axonal neuropathy in a pediatric patient

  2024cites this paper
• Variation in worldwide incidence of Guillain-Barré syndrome: a population-based study in urban China and existing global evidence

  2024cites this paper
• Post-licensure Safety Surveillance of 20-Valent Pneumococcal Conjugate Vaccine (PCV20) Among US Adults in the Vaccine Adverse Event Reporting System (VAERS)

  2024cites this paper
• [A case of anti-ganglioside antibody-positive Guillain-Barré syndrome with asymmetrical muscle weakness throughout the course of the disease].

  2024cites this paper
• An Overview of Zika Virus and Zika Virus Induced Neuropathies

  2024cites this paper
• Validating ICD-10 Diagnosis Codes for Guillain-Barré Syndrome in Taiwan’s National Health Insurance Claims Database

  2024cites this paper
• Superposición de síndrome de Miller-Fisher/Guillain-Barré posterior a vacuna contra COVID-19

  2024cites this paper
• Correlation of Clinical and Electrophysiological Criteria in the Diagnosis of Guillain-Barré Syndrome: A Prospective Observational Study.

  2024cites this paper
• Genomic variability in Zika virus in GBS cases in Colombia

  2024cites this paper
• Unveiling the Devastating Impact of Atypical and Rapidly Evolving Guillain-Barre Syndrome: A Report of Two Cases

  2024cites this paper
• Efeitos do laser e ultrassom terapêuticos combinados na polineuropatia periférica na síndrome de Guillain-Barré: estudo de caso

  2024cites this paper
• Clinical presentation and symptomatology of Guillain-Barré syndrome: A literature review

  2024cites this paper
• Efficacy and safety of eculizumab in Guillain‐Barré syndrome: A phase 3, multicenter, double‐blind, randomized, placebo‐controlled clinical trial

  2024cites this paper
• A short-term functional recovery comparison of therapeutic plasma exchange and immunoadsorption in severe acute neuroimmune diseases.

  2024cites this paper
• Applicability of selected Brighton Collaboration case definitions in low-resource settings: A prospective hospital-based active surveillance in Addis Ababa, Ethiopia

  2024cites this paper
• Utilizing nerve conduction studies to identify very early Guillain–Barré syndrome and distinguish it from mimics in emergency settings

  2024cites this paper
• Early Safety Findings Among Persons Aged ≥60 Years Who Received a Respiratory Syncytial Virus Vaccine — United States, May 3, 2023–April 14, 2024

  2024cites this paper
• Rapid Improvement in Guillain-Barré Syndrome With Demyelinating and Secondary Axonal Involvement: A Case Report

  2024cites this paper
• Understanding the diagnostic challenges of Miller Fisher syndrome in children: a case report from an ophthalmological perspective.

  2024cites this paper
• Varicella Outbreak Among Recent Arrivals to New York City, 2022–2024

  2024cites this paper
• Effectiveness of Methylprednisolone against COVID-19–related Guillain–Barré Syndrome: A Single Case Report

  2024cites this paper
• Clinical, paraclinical and outcome features of 166 patients with acute anti-GQ1b antibody syndrome

  2024cites this paper
• Clinical predictors for mechanical ventilation assistance in Guillain-Barré syndrome

  2024cites this paper
• Enhancing Tone and Strength in a Patient With Autoimmune Encephalitis and Guillain-Barré Syndrome Using Rood’s Facilitatory Techniques and Neuromuscular Electrical Stimulation: A Case Report

  2024cites this paper
• Hantavirus infection-related acute inflammatory demyelinative polyradiculoneuropathy: A case report and literature review

  2024cites this paper
• Takotsubo cardiomyopathy in Guillain–Barré syndrome

  2024cites this paper
• Electrodiagnostic studies and new diagnostic modalities for evaluation of peripheral nerve disorders

  2024cites this paper
• Canadian vaccine safety surveillance reports following immunization with seasonal influenza vaccines, 2021–2022

  2024cites this paper
• What Is in the Literature.

  2024cites this paper
• Neuromuscular problems of the critically Ill neonate and child.

  2024cites this paper
• Electrodiagnostic methods to verify Guillain‐Barré syndrome subtypes in Istanbul: A prospective multicenter study

  2024cites this paper
• Long-term outcomes of plasma exchange versus intravenous immunoglobulin for the treatment of Guillain-Barré Syndrome: A double-blind, randomized clinical trial

  2024cites this paper
• Lessons learned from COVID-19, H1N1, and routine vaccine pharmacovigilance in the United States: a path to a more robust vaccine safety program

  2024cites this paper
• Safety of Simultaneous Administration of Bivalent mRNA COVID-19 and Influenza Vaccines in the Vaccine Adverse Event Reporting System (VAERS)

  2024cites this paper
• Síndrome de Miller Fisher: un caso desafiante para el diagnóstico diferencial

  2024cites this paper
• Guillain–Barre syndrome following scrub typhus: a case report and literature review

  2024cites this paper
• Neurofilament light chain as a diagnostic and prognostic biomarker in Guillain–Barré syndrome

  2024cites this paper
• The Impact of COVID-19 on the Guillain–Barré Syndrome Incidence

  2024cites this paper
• New chronic inflammatory demyelinating polyneuropathy/Guillain–Barré syndrome guidelines – impact on clinical practise

  2024cites this paper
• Poliradicoloneurite acuta demielinizzante o sindrome di Guillain-Barré

  2023cites this paper
• Validation of elevated levels of interleukin-8 in the cerebrospinal fluid, and discovery of new biomarkers in patients with GBS and CIDP using a proximity extension assay

  2023cites this paper
• European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain–Barré syndrome

  2023cites this paper
• Rule out alternative causes before attributing polyradiculitis to influenza or severe acute respiratory syndrome coronavirus 2 vaccination

  2023cites this paper
• COVID-19 Vaccines for Optimizing Immunity in the Upper Respiratory Tract

  2023cites this paper
• [Guillain-Barre syndrome in children].

  2023cites this paper
• High risk and low prevalence diseases: Guillain-Barré syndrome.

  2023cites this paper
• Emerging biomarkers to predict clinical outcomes in Guillain–Barré syndrome

  2023cites this paper
• Immunogenicity and Safety Following 1 Dose of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults: A Phase 3 Trial

  2023cites this paper
• Diagnostic odyssey of Guillain-Barré syndrome in children.

  2023cites this paper